Liposomal delivery of α-interferon to murine bladder tumor cells via transferrin receptor-mediated endocytosis

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 5, Issue 2, 1998, Pages 111-118

  Liao, Wen Pin ^a   DeHaven, Jean ^b   Shao, Jun ^a   Chen, Jian Xing ^a   Rojanasakul, Yongyut ^a   Lamm, Donald L ^b   Ma, Joseph K H ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Correlation between Uptake and Antiproliferative Activity; Endocytosis; MBT2 Cells; TFPL Liposomes; Interferon

Indexed keywords

ALPHA INTERFERON; DIPALMITOYLPHOSPHATIDYLCHOLINE; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; POLYLYSINE; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; ENDOCYTOSIS; INTRAVESICAL DRUG ADMINISTRATION; IRON TRANSPORT; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031811220     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.3109/10717549809031386     Document Type: Article

References (22)

1. 125I-labeled mouse interferon to a specific cell surface receptor. Nature 284:459-461.
2. Bangham, A. D., Standish, M. M., and Watkins, J. C. 1965. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13:238-252.
3. Borden, E. C., Groveman, D. S., Nasu, T., Reznikoff, C., and Bryan, G. T. 1984. Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J. Urol. 132:800-803.
4. Faulk, W. P., Hsi, B. L., and Stevens, P. J. 1980. Transferrin and transferrin receptors in carcinoma of breast. Lancet 2:390-392.
5. Frangos, D. N., Killion, J. J., Fan, D., Fishbeck, R., Eschenbach, A. C., and Fidler, I. J. 1990. The development of liposomes containing interferon-α for the intravesical therapy of human superficial bladder cancer. J. Urol. 143:1252-1256.
6. Glashan, R. W. 1990. A randomized controlled study of intravesical a-2b-interferon in carcinoma in situ of the bladder. J. Urol. 144:658-661.
7. Harrison, G. S. M., Green, D. F., Neuling, D. W. W., Richards, B., Robison, M. R. G., and Smith, P. H. 1983. A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. Br. J. Urol. 55:676-679.
8. Hoeltl, W., Hasun, R., Albrecht, W., and Marbergger, M. 1991. How effective is topical α-2b interferon in preventing recurrence of superficial bladder cancer? Br. J. Urol. 68:495-498.
9. Jones, M. N. 1995. The surface properties of phospholipid liposome systems and their characterization. Adv. Colloid Interface Sci. 54:93-128.
10. Kalble, T., Beer, M., and Staehler, G. 1994. Intravesical prophylaxis with BCG versus interferon-α for superficial bladder cancer. J. Urol. 150:232A.
11. Killion, J. J., Fan, D., Bucana, C. D., Frangos, D. N., Price, J. E., and Fidler, I. J. 1989. Augmentation of antiproliferative activity of interferon-α against human bladder tumor cell lines by encapsulation of interferon-α within liposomes. J. Natl. Cancer Inst. 81:1387-1392.
12. Killion, J. J., Fishbeck, R., Bar-Eli, M., and Chernajovsky, Y. 1994. Delivery of interferon to intracellular pathways by encapsulation into multilamellar liposomes is independent of the status of interferon receptors. Cytokine 6:443-449.
13. Kumar, R., and Atlas, I. 1992. Interferon-α induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: Role in growth regulation. Proc. Natl. Acad. Sci. USA 89:6599-6603.
14. Kuroki, T., Takeda, T., Nishiguchi, S., Otani, S., and Kobayashi, K. 1993. Inhibition of intracellular putrescine by interferons to suppress growth of human hepatoma cells. Proc. Am. Assoc. Cancer Res. 34:A236.
15. Lamm, D. L., Riggs, D. R., Traynelis, C. L., and Nseyo, U. O. 1995. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol. 153:1444-1450.
16. Lattime, E. C., Gomella, L. G., and McCue, P. A. 1992. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T cells. Cancer Res. 52:4286-4290.
17. Mogensen, K. E., and Bandu, M. T. 1983. Kinetic evidence for an activation step following binding of human interferon-α to the membrane receptors of Daudi cells. Eur. J. Biochem. 134:355-364.
18. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. 1997. Cancer statistics. Ca-A Cancer J. Clinicians 47:5-27.
19. Torti, F. M., Shortlffe, L. D., Williams, R. D., Pitts, W. C., Kempson, R. L., Ross, J. C., Palmer, J., Meyers, F., Ferrari, M., Hannigan, J., Spiegel, R., Mcwriter, K., and Freiha, F. 1988. Alpha-interferon in superficial bladder cancer: A northern California oncology group study. J. Clin. Oncol. 6:476-483.
20. Tovey, M. G., Dron, M., Mogensen, K. E., Lebleu, B., Mechti, N., and Bego-Lours-Guymarho, J. 1983. Isolation of Daudi cells with reduced sensitivity to interferon. II. On the mechanisms of resistance. J. Genet. Virol. 64:2649-2653.
21. Verhaegen, M., Divizia, M., Vandenbussche, P., Kuwata, T., and Content, J. 1980. Abnormal behavior of interferon-induced enzymatic activities in an interferon-resistant cell line. Proc. Natl. Acad. Sci. USA 77:4479-4483.
22. Zincke, H., Utz, D. C., Taylor, W. F., Meyers, R. P., and Leary, F. J. 1983. Influence of thiotepa doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: A prospective, randomized, double blind, controlled trial. J. Urol. 129:505-509.